↓ Skip to main content

Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial

Overview of attention for article published in Inflammopharmacology, December 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#7 of 282)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news
3 news outlets
blogs
1 blog
twitter
12 tweeters
facebook
3 Facebook pages
video
2 video uploaders

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
68 Mendeley
Title
Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial
Published in
Inflammopharmacology, December 2012
DOI 10.1007/s10787-012-0163-3
Pubmed ID
Authors

K. Madhu, K. Chanda, M. J. Saji

Abstract

Curcuma longa Linn. is widely used for the treatment of disorders associated with inflammation and was evaluated for its safety and efficacy in the treatment of painful knee osteoarthritis (OA). This was a randomized, single blind, placebo-controlled trial. Total of 120 patients (37 males and 83 females) with primary knee OA received either placebo (400 mg twice daily) or NR-INF-02 (500 mg twice daily) or glucosamine sulphate (GS) (750 mg twice daily) alone or combination of NR-INF-02 and GS for 42 days. The efficacy was assessed during treatment period, on day 21 and day 42. The decrease in severity of pain symptom and function of affected knee as primary efficacy outcome measure was assessed by Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, respectively. The clinical examination of affected joint was measured by an orthopaedic specialist and using a Clinician Global Impression Change (CGIC) scale. The analysis of post-treatment scores following administration of NR-INF-02 using VAS, WOMAC, and CGIC at each clinical visit showed significant decrease (p < 0.05) compared to placebo. NR-INF-02 treated group showed a significant (p < 0.01) decrease in use of rescue medication, along with clinical and subjective improvement compared to placebo. The tolerability and acceptability profile of NR-INF-02 was better during the trial period. The study demonstrates safety and efficacy of NR-INF-02 as a useful treatment option for patients with primary painful knee OA.

Twitter Demographics

The data shown below were collected from the profiles of 12 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mexico 1 1%
United States 1 1%
Unknown 66 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 23 34%
Researcher 9 13%
Student > Master 8 12%
Unspecified 8 12%
Student > Postgraduate 5 7%
Other 15 22%
Readers by discipline Count As %
Medicine and Dentistry 24 35%
Nursing and Health Professions 13 19%
Unspecified 10 15%
Agricultural and Biological Sciences 7 10%
Pharmacology, Toxicology and Pharmaceutical Science 6 9%
Other 8 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 July 2019.
All research outputs
#457,994
of 13,420,122 outputs
Outputs from Inflammopharmacology
#7
of 282 outputs
Outputs of similar age
#7,126
of 249,729 outputs
Outputs of similar age from Inflammopharmacology
#2
of 7 outputs
Altmetric has tracked 13,420,122 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 282 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 249,729 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.